Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07116057) titled 'MOv19-BBz CAR T Cells in FRa+ Cancers' on Aug. 4.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: University of Pennsylvania
Condition:
Metastatic Non Small Cell Lung Cancer
Recurrent Lung Non-Small Cell Carcinoma
Intervention:
Biological: MOv19-BBz CAR T cells
Drug: Cyclophosphamide/Fludarabine
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: October 2025
Target Sample Size: 10
Countries of Recruitment:
United States
To know more, visit ht...